Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum CVR Medical Corp V.CVM.H

Alternate Symbol(s):  CRRVF

CVR Medical Corp. is a medical technology organization. The Company is focused on the development and advancement of technology at work within the healthcare sector. The Company’s Carotid Stenotic Scan (CSS) is a diagnostic tool designed to detect and determine a level of carotid narrowing for the purpose of identifying patients at risk for Ischemic Stroke. The CSS provides a synergistic tool... see more

TSXV:CVM.H - Post Discussion

CVR Medical Corp > Financials
View:
Post by OleMule on Aug 12, 2020 9:26am

Financials

More of the same bullcrap.  I do find it odd that in the MD&A it states:

"In March 2020, CVR Medical and CVR Global reached a tentative agreement for restructuring the two companies. CVR Medical is to receive all the Intellectual Property (IP) relating to Infrasonic, Subsonic and Low Frequency Ultrasound in exchange for shares of CVR Medical Stock. An independent valuation of the IP is to be done to determine the share amount. The details of the restructuring plan are being finalized at which time the agreement will be presented to the TSX-v for a pre-approval process to be followed by a special meeting of the shareholders for ratification. The Board of Directors agree unanimously that the restructuring agreement is in the best interest of the CVR Medical shareholders. As a stand-alone Medical Device Company, CVR Medical takes possession of the CSS and all future devices that may be in the pipeline."

Yet on June 8th, 2020, Paul Blunden put out a press release stating that the agreement had been cancelled and rescinded.  Which is it Paul?  

Who will do the independent valuation, the same firm that conducted the valuation on CVR GLobal?  That was a farce, what was gleamed from that egregious valuation was everything was overstated including Peter Balema's and Global's contribution which they touted at $8M/$24M respectiviely yet the CVR Global Balance stated a MUCH different picture.

Come on Blunden tell the world the "NEW" plan 
Comment by OleMule on Aug 12, 2020 4:37pm
Forgot to state off course the all unanimously agree with the exception of Trush, they are all either stakeholders and or large debt holders (services billed  to CVR Med) in Global who wouldn't want more shares of Medical issued for IP that we do don't need. Medical already owns the rights globally for stroke why should we issue/dilute shares for applications that are years and ...more  
Comment by Nastro on Aug 12, 2020 6:19pm
I have zero faith the 'valuation' put on the IP will be anything other than ridiculous and the potential dilution coming our way utterly obscene.  
Comment by Growth100Percnt on Aug 15, 2020 8:50am
At least we seem to be moving forward. They actually found some cash to file the Q1 results.
Comment by Growth100Percnt on Aug 15, 2020 8:53am
I suspect Q2 must be due as well??
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities